# 2026-17084: FDA Keeps Cancer Drug Experts on Payroll Till 2028

2026-17084, Advisory Committee; Oncologic Drugs Advisory Committee; Renewal, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-21, effective Authority for the Oncologic Drugs Advisory Committee will expire on September 1, 2026, unless the Commissioner formally determines that renewal is in the public interest. (as of 2026-08-28).

- Canonical: https://policyrisk.com/federal-register/2026-17084
- As of: 2026-08-28
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-17084
- Title: Advisory Committee; Oncologic Drugs Advisory Committee; Renewal
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 54332
- Published: 2026-08-21
- Effective: Authority for the Oncologic Drugs Advisory Committee will expire on September 1, 2026, unless the Commissioner formally determines that renewal is in the public interest.
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-28

## In one line

FDA Keeps Cancer Drug Experts on Payroll Till 2028

## Summary

The FDA is renewing its Oncologic Drugs Advisory Committee for two more years, keeping cancer drug experts on board until September 1, 2028. This group helps the FDA make sure cancer medicines are safe and effective, affecting patients, doctors, and drug makers. No new costs or deadlines for the public, just continued expert advice to keep cancer treatments top-notch.

## Abstract

The Food and Drug Administration (FDA) is announcing the renewal of the Oncologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Oncologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the September 1, 2028, expiration date.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-17084 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/21/2026-17084/advisory-committee-oncologic-drugs-advisory-committee-renewal)
- [2026-17084 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-21/pdf/2026-17084.pdf)

## Related
- [Previous: 2026-17083, 30-Day Notice of Proposed Information Collection: Requirements for Designating…](https://policyrisk.com/federal-register/2026-17083)
- [Next: 2026-17085, 30-Day Notice of Proposed Information Collection: Electronic Line of Credit Con…](https://policyrisk.com/federal-register/2026-17085)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-17084 (as of 2026-08-28).
